Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 1999

View Archived Issues

Hemopure receives fast track status in South Africa

Genzyme Tissue Repair's TGF-beta2 sponge evaluated in phase II diabetic foot ulcers

HMR and Sepracor resolve issues relating to fexofenadine

Exocell receives patents for diabetic kidney disease therapy

Licensing opportunity from NIH: geldanamycins as inhibitors of the HGF/SF-Met pathway

HMR and Vertex expand antiinflammatory drug discovery agreement

AutoImmune reports disappointing phase III trial results for Colloral

Chinese researchers publish synthesis and activity data for novel antifungal agents

PowderJect begins clinical study of DNA malaria vaccine

Mechanism of anogenital wart clearance by imiquimod investigated in clinical trial

Synagis approved in Europe for prevention of RSV

Orally active prodigiosine compounds claimed for immunosuppression, Rx of T-cell leukemia-lymphoma

Prodrugs of BK(Ca) channel modulators from BMS particularly useful for cerebral ischemia/stroke

Darwin's new MMP inhibitors useful for degenerative diseases, cancer, etc.

German lab discovers novel potential antipsychotic agents: ustilipids

Cubist continues to target bacterial enzymes for development of novel antibiotics

Results of SAR studies on PD-151307 analogues presented at ACS meeting

Potent protein farnesyltransferase inhibitors emerge from Parke-Davis program

Potent new analgesic/antiinflammatory agents developed in China

Zomig launched in China for treatment of migraine

Shenyang Pharmaceutical University synthesizes new antiulcer benzimidazoles

HMR-1883 prevents IK(ATP) activation-induced action potential shortening in human cardiomyocytes

Synthesis and mechanism of action of a natural compound acting on a previously undefined target

Post-MI SARA associated with attenuation of reactive fibrosis and ventricular remodeling

Mortality benefit shown for levosimendan in severe decompensated heart failure

FDA approves 50-mg vial of Abelcet for severe fungal infections

Orally bioavailable, ETB receptor-selective antagonists designed by Abbott

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026